Tags

Type your tag names separated by a space and hit enter

Emergency Authorization of Chloroquine and Hydroxychloroquine for Treatment of COVID-19.
Ann Pharmacother. 2020 08; 54(8):827-831.AP

Abstract

The world is suffering a respiratory pandemic disease caused by a novel coronavirus (2019-nCoV), commonly known as COVID-19 (coronavirus disease 2019). The Food and Drug Administration issued an emergency authorization for chloroquine and hydroxychloroquine as experimental treatments for COVID-19 leading to a shortage of both medications. A literature review conducted in April 2020 shows a lack of high-quality data available, resulting in ambiguous guideline recommendations. Decisions to use either drug should be made with careful consideration of risks versus benefits along with proper monitoring. Because of its higher potency and better safety profile, hydroxychloroquine may be the more reasonable treatment option if treatment is initiated.

Authors+Show Affiliations

University of Florida, Gainesville, FL, USA.University of Florida, Gainesville, FL, USA.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32389025

Citation

Piszczatoski, Christopher R., and Jason Powell. "Emergency Authorization of Chloroquine and Hydroxychloroquine for Treatment of COVID-19." The Annals of Pharmacotherapy, vol. 54, no. 8, 2020, pp. 827-831.
Piszczatoski CR, Powell J. Emergency Authorization of Chloroquine and Hydroxychloroquine for Treatment of COVID-19. Ann Pharmacother. 2020;54(8):827-831.
Piszczatoski, C. R., & Powell, J. (2020). Emergency Authorization of Chloroquine and Hydroxychloroquine for Treatment of COVID-19. The Annals of Pharmacotherapy, 54(8), 827-831. https://doi.org/10.1177/1060028020925558
Piszczatoski CR, Powell J. Emergency Authorization of Chloroquine and Hydroxychloroquine for Treatment of COVID-19. Ann Pharmacother. 2020;54(8):827-831. PubMed PMID: 32389025.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Emergency Authorization of Chloroquine and Hydroxychloroquine for Treatment of COVID-19. AU - Piszczatoski,Christopher R, AU - Powell,Jason, Y1 - 2020/05/09/ PY - 2020/5/12/pubmed PY - 2020/7/14/medline PY - 2020/5/12/entrez KW - COVID-19 KW - SARS-CoV-2 KW - chloroquine KW - coronavirus KW - hydroxychloroquine KW - nCoV-2019 SP - 827 EP - 831 JF - The Annals of pharmacotherapy JO - Ann Pharmacother VL - 54 IS - 8 N2 - The world is suffering a respiratory pandemic disease caused by a novel coronavirus (2019-nCoV), commonly known as COVID-19 (coronavirus disease 2019). The Food and Drug Administration issued an emergency authorization for chloroquine and hydroxychloroquine as experimental treatments for COVID-19 leading to a shortage of both medications. A literature review conducted in April 2020 shows a lack of high-quality data available, resulting in ambiguous guideline recommendations. Decisions to use either drug should be made with careful consideration of risks versus benefits along with proper monitoring. Because of its higher potency and better safety profile, hydroxychloroquine may be the more reasonable treatment option if treatment is initiated. SN - 1542-6270 UR - https://www.unboundmedicine.com/medline/citation/32389025/Emergency_Authorization_of_Chloroquine_and_Hydroxychloroquine_for_Treatment_of_COVID_19_ DB - PRIME DP - Unbound Medicine ER -